Daxor Corporation announced an expert analysis titled, “Anemia and Heart Failure: Guidance for Clinicians and Trialists'' published July 6, 2021 in the American College of Cardiology (ACC) online clinical topics section. The authors focus on detecting and addressing anemia in heart failure (HF) patients, a common and often unrecognized condition causing increased length of hospitalization and worsening outcomes. The document specifically states, “every attempt should be made to measure and know total blood volume” and cites outcome studies that identify total blood volume via Daxor's unique blood volume analysis technology. In addition to its current FDA-cleared BVA-100 blood test, Daxor is developing next-generation testing platforms under multiple contract awards with the U.S. Department of Defense and support from the National Institutes of Health, slated for release in 2022.